JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265848

Human ZRANB1 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ZRANB1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

DKFZp762P2216, TRAF-binding protein domain, Trabid, Ubiquitin thioesterase ZRANB1, ZRAN1_HUMAN, Zinc finger Ran-binding domain-containing protein 1, hTrabid

1 Images
Sanger Sequencing - Human ZRANB1 knockout HeLa cell line (AB265848)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZRANB1 knockout HeLa cell line (AB265848)

Homozygous : 1 bp insertion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265848-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265848 Human ZRANB1 knockout HeLa cell line", "number":"AB265848-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265848-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265848-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265848-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265848 Human ZRANB1 knockout HeLa cell line", "number":"AB265848-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265848-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265848 Human ZRANB1 knockout HeLa cell line", "number":"AB265848-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265848-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265848 Human ZRANB1 knockout HeLa cell line", "number":"AB265848-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ZRANB1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ZRANB1 also known as TRABID is a zinc finger RANBP2-type containing 1 protein with a mass of approximately 89 kDa. This protein functions majorly as a deubiquitinating enzyme specializing in cleaving Lys29- and Lys33-linked polyubiquitin chains. It is expressed across various tissues with notable expression in the human brain indicating its importance in neural functions. Mechanically ZRANB1 contains several zinc finger motifs which facilitate its interaction with ubiquitin substrates playing a critical role in protein ubiquitination homeostasis.
Biological function summary

ZRANB1 acts in the regulation of protein degradation and turnover impacting various cellular processes like signal transduction and cell cycle control. It functions as part of the ubiquitin-proteasome system which is a large multi-protein complex responsible for maintaining cellular protein homeostasis. Through its activity ZRANB1 influences not only regular cellular operations but also responds to stress signals by adjusting the degradation of proteins therefore impacting numerous physiological processes.

Pathways

ZRANB1 participates in the Wnt signaling pathway and the NF-kB pathway both of which are important for cell proliferation and immune response regulation. In the Wnt pathway it regulates the stability and signaling activity of key proteins like beta-catenin. Meanwhile ZRANB1's action in the NF-kB pathway involves modulating the degradation of ubiquitinated proteins with relations to proteins like NEMO. These pathways highlight the specific regulatory roles played by ZRANB1 within signaling networks.

ZRANB1 has been implicated in cancer and neurological disorders. In cancer aberrant regulation or mutations in ZRANB1 can lead to uncontrolled cell growth due to misregulation of the Wnt signaling pathway. In neurological disorders potential links to proteins involved in neural development highlight its role in maintaining neural homeostasis. By influencing pathways connected to these diseases ZRANB1 interacts with other proteins such as APC in cancer and possibly tau proteins in neurodegenerative disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com